Основная статистика
| CIK | 1599901 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Avidity Biosciences, Inc.
SEC Filings (Chronological Order)
На этой странице представлен полный хронологический список документов SEC, за исключением документов о собственности, которые мы предоставляем в других местах.
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 1, 2025 AVIDITY BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39321 46-1336960 (State or other jurisdiction of incorporation or organiza |
|
| August 7, 2025 |
Exhibit 99.1 Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights Aligned with FDA on del-brax accelerated and full approval pathways for FSHD, reported positive topline data from Phase 1/2 FORTITUDE™ trial, and initiated global confirmatory Phase 3 study Planned del-zota BLA submission at year end 2025 for DMD44 on track to be Avidity’s first BLA submission On t |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2025 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-39321 Avidity Biosciences, Inc. (Exact name |
|
| July 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 23, 2025 AVIDITY BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39321 46-1336960 (State or other jurisdiction of incorporation or organizat |
|
| June 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 10, 2025 AVIDITY BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39321 46-1336960 (State or other jurisdiction of incorporation or organizat |
|
| June 9, 2025 |
EX-99.1 June 9, 2025 NASDAQ: RNA | aviditybio.com Investor & Analyst Event Series Delivering for People Living with Facioscapulohumeral Muscular Dystrophy (FSHD) Exhibit 99.1 Forward-Looking Statements We caution the reader that this presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements other than statements of historical fact contained i |
|
| June 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 9, 2025 AVIDITY BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39321 46-1336960 (State or other jurisdiction of incorporation or organizati |
|
| May 8, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 8, 2025 AVIDITY BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39321 46-1336960 (State or other jurisdiction of incorporation or organizatio |
|
| May 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2025 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-39321 Avidity Biosciences, Inc. (Exact name |
|
| May 8, 2025 |
on-Employee Director Compensation P rna-20250331xex101avidit Exhibit 10.1 1 AVIDITY BIOSCIENCES, INC. NON-EMPLOYEE DIRECTOR COMPENSATION PROGRAM (As Amended and Restated Effective April 1, 2025) Non-employee members of the board of directors (the “Board”) of Avidity Biosciences, Inc. (the “Company”) shall receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (as amended to date, this “P |
|
| May 8, 2025 |
Exhibit 99.1 Avidity Biosciences Reports First Quarter 2025 Financial Results and Recent Highlights On track to deliver key regulatory updates for del-brax and topline data from dose escalation cohorts in the FORTITUDETM trial in the second quarter Positive topline del-zota data further supports first BLA submission at year end 2025 – continues to highlight reproducibility and consistency across t |
|
| May 8, 2025 |
, by and between Turning Point Therapeutics, Inc. and the Registrant. rna-20250331xex102firsta Exhibit 10.2 Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Such omitted information has been noted in this document with a placeholder identified by the mark “[***]”. First Amendment to Sublease Agreement This First Amendment to Sublease Agreement (th |
|
| April 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin |
|
| April 29, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| April 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 25, 2025 AVIDITY BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39321 46-1336960 (State or other jurisdiction of incorporation or organiza |
|
| April 29, 2025 |
Letter to Securities and Exchange Commission from BDO USA, P.C., dated April 28, 2025. exhibit161 April 28, 2025 Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 We have been furnished with a copy of the response to Item 4.01 of Form 8-K for the event that occurred on April 25, 2025, to be filed by Avidity Biosciences, Inc. We agree with the statements made in response to that Item insofar as they relate to our Firm. Very truly yours, /s/ BDO USA, P.C. |
|
| March 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 19, 2025 AVIDITY BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39321 46-1336960 (State or other jurisdiction of incorporation or organiza |
|
| March 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 17, 2025 AVIDITY BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39321 46-1336960 (State or other jurisdiction of incorporation or organiza |
|
| March 17, 2025 |
1 March 17, 2025 NASDAQ: RNA | aviditybio.com Investor & Analyst Event Transforming Duchenne Muscular Dystrophy (DMD) Del-zota EXPLORE44® Phase 1/2 Topline Data 2 We caution the reader that this presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements other than statements of historical fact contained in this presentation are forward-looking |
|
| February 27, 2025 |
Amended and Restated Employment Agreement, dated Exhibit 10.12 US-DOCS\152924696.1 August 26, 2024 VIA EMAIL Steven Hughes, M.D. c/o Avidity Biosciences, Inc. 10578 Science Center Drive, Suite 125 San Diego, CA 92121 Re: Amended and Restated Employment Agreement Dear Steve: Avidity Biosciences, Inc. (the “Company”) and you entered into that certain Employment Agreement, dated as of December 22, 2021 (the “Prior Agreement”). The Company and you d |
|
| February 27, 2025 |
Exhibit 99.1 Avidity Biosciences Reports Fourth Quarter 2024 Financial Results and Recent Highlights Building on success across its three clinical programs, Avidity is leading in rare neuromuscular diseases with a strong balance sheet to execute on a transformational 2025 Major milestones anticipated for each rare neuromuscular program in 2025, including preparing for Avidity’s first BLA submissio |
|
| February 27, 2025 |
As filed with the Securities and Exchange Commission on February 27, 2025 As filed with the Securities and Exchange Commission on February 27, 2025 Registration No. |
|
| February 27, 2025 |
Amended and Restated Employment Agreement, dated Exhibit 10.13 US-DOCS\153613346.2 August 29, 2024 VIA EMAIL Kathleen Gallagher c/o Avidity Biosciences, Inc. 10578 Science Center Drive, Suite 125 San Diego, CA 92121 Re: Amended and Restated Employment Agreement Dear Kath: Avidity Biosciences, Inc. (the “Company”) and you entered into that certain Employment Agreement, dated as of April 22, 2021 (the “Prior Agreement”). The Company and you desire |
|
| February 27, 2025 |
Exhibit 107 CALCULATION OF FILING FEE TABLE Form S-8 (Form Type) Avidity Biosciences, Inc. |
|
| February 27, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 27, 2025 AVIDITY BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39321 46-1336960 (State or other jurisdiction of incorporation or organ |
|
| February 27, 2025 |
Exhibit 10.15 US-DOCS\156140015.2 December 12, 2024 VIA EMAIL Charles Calderaro III [email protected] Re: Offer of Employment and Employment Agreement Dear Chuck: Avidity Biosciences, Inc. (the “Company”) is pleased to offer you employment as the Company’s Chief Technology Officer on the terms and conditions set forth in this letter agreement (the “Agreement”). 1. Commencement of Emplo |
|
| February 27, 2025 |
Amended and Restated Employment Agreement, dated Exhibit 10.14 US-DOCS\152924874.1 August 26, 2024 VIA EMAIL Eric Mosbrooker c/o Avidity Biosciences, Inc. 10578 Science Center Drive, Suite 125 San Diego, CA 92121 Re: Amended and Restated Employment Agreement Dear Eric: Avidity Biosciences, Inc. (the “Company”) and you entered into that Employment Agreement, dated as of January 1, 2024 (the “Prior Agreement”). The Company and you desire to amend |
|
| February 27, 2025 |
nsider Trading Compliance Policy and Procedures Exhibit 19.1 1 Avidity Biosciences, Inc. Insider Trading Compliance Policy and Procedures (amended and restated as of February 19, 2025) Federal and state laws prohibit trading in the securities of a company while in possession of material nonpublic information and in breach of a duty of trust or confidence. These laws also prohibit anyone who is aware of material nonpublic information from provid |
|
| February 27, 2025 |
ublease Agreement, dated April 29, 2024, by and between Turning Point Therapeutics, Inc. and Exhibit 10.20 Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Such omitted information has been noted in this document with a placeholder identified by the mark “[***]”. SUBLEASE AGREEMENT This Sublease Agreement (this “Sublease”) is made and entered as of April 29, 2024, by an |
|
| February 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number: 001-39321 AVIDITY BIOSCIENCES, INC. |
|
| January 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 8, 2025 AVIDITY BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39321 46-1336960 (State or other jurisdiction of incorporation or organiz |
|
| November 14, 2024 |
RNA / Avidity Biosciences, Inc. / RA CAPITAL MANAGEMENT, L.P. - SC 13G/A Passive Investment SC 13G/A 1 tm2427451d10sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Avidity Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 05370A108 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Stat |
|
| November 14, 2024 |
EX-99.1 2 tm2427451d10ex1.htm EXHIBIT 1 EXHIBIT 1 AGREEMENT This Joint Filing Agreement, dated as of November 14, 2024 is by and among RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (the foregoing are collectively referred to herein as the “Filers”). Each of the Filers may be required to file with the United States Securities and Exchange Commissio |
|
| November 14, 2024 |
SC 13G 1 p24-3108sc13g.htm AVIDITY BIOSCIENCES, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Avidity Biosciences, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 05370A108 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of This Statement) Check the |
|
| November 14, 2024 |
JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) EX-1 2 p24-3108exhibit1.htm JOINT FILING AGREEMENT PURSUANT TO RULE 13D-1(K) EXHIBIT 1 JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the ne |
|
| November 13, 2024 |
SC 13G/A 1 rnaa3111224.htm COWEN FINANCIAL PRODUCTS LLC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Avidity Biosciences, Inc (Name of Issuer) Common Stock (Title of Class of Securities) 05370A108 (CUSIP Number) September 30, 2024 (Date of Event which Requires Filing of this Statement) Check the ap |
|
| November 13, 2024 |
RNA / Avidity Biosciences, Inc. / BRISTOL MYERS SQUIBB CO - SC 13G/A Passive Investment SC 13G/A 1 ef20038544sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Avidity Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 05370A108 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statemen |
|
| November 12, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 12, 2024 AVIDITY BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39321 46-1336960 (State or other jurisdiction of incorporation or organ |
|
| November 12, 2024 |
1 Investor & Analyst Event Series – Volume 11 Precision Cardiology: Transforming Genetic Cardiomyopathy Treatment & First Look at Next-Generation Innovations November 12, 2024 NASDAQ: RNA | aviditybio. |
|
| November 8, 2024 |
EX-99 2 Rule13DJointFilingAgreement.htm JOINT FILING AGREEMENT JOINT FILING AGREEMENT The undersigned hereby agree that this Schedule 13G (the “Schedule 13G”) with respect to the common stock of Avidity Biosciences, Inc. is, and any additional amendment thereto signed by each of the undersigned shall be, filed on behalf of each undersigned pursuant to and in accordance with the provisions of 13d-1 |
|
| November 8, 2024 |
SC 13G 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Avidity Biosciences, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 05370A108 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box |
|
| November 7, 2024 |
Amended and Restated Employment Agreement, dated August 26, 2024, by and between rna-20240930xex105amende Exhibit 10.5 US-DOCS\152924232.1 August 26, 2024 VIA EMAIL Teresa McCarthy c/o Avidity Biosciences, Inc. 10578 Science Center Drive, Suite 125 San Diego, CA 92121 Re: Amended and Restated Employment Agreement Dear Teresa: Avidity Biosciences, Inc. (the “Company”) and you entered into that certain Employment Agreement, dated as of August 14, 2020 (the “Prior Agreement”). Th |
|
| November 7, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 7, 2024 AVIDITY BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39321 46-1336960 (State or other jurisdiction of incorporation or organi |
|
| November 7, 2024 |
Amended and Restated Employment Agreement, dated August 26, 2024, by and between rna-20240930xex106amende Exhibit 10.6 US-DOCS\152924433.1 August 26, 2024 VIA EMAIL John B. Moriarty, Jr. c/o Avidity Biosciences, Inc. 10578 Science Center Drive, Suite 125 San Diego, CA 92121 Re: Amended and Restated Employment Agreement Dear John: Avidity Biosciences, Inc. (the “Company”) and you entered into that certain Employment Agreement, dated as of July 31, 2024 (the “Prior Agreement”). |
|
| November 7, 2024 |
Amended and Restated Employment Agreement, dated August 26, 2024, by and between rna-20240930xex103amende Exhibit 10.3 US-DOCS\152925120.1 August 26, 2024 VIA EMAIL Michael F. MacLean c/o Avidity Biosciences, Inc. 10578 Science Center Drive, Suite 125 San Diego, CA 92121 Re: Amended and Restated Employment Agreement Dear Mike: Avidity Biosciences, Inc. (the “Company”) and you entered into that certain Employment Agreement, dated as of May 14, 2020 (the “Prior Agreement”). The |
|
| November 7, 2024 |
Amended and Restated Employment Agreement, dated August 26, 2024, by and between rna-20240930xex102amende Exhibit 10.2 US-DOCS\150944263.7 August 26, 2024 Sarah Boyce c/o Avidity Biosciences, Inc. 10578 Science Center Drive, Suite 125 San Diego, CA 92121 Re: Amended and Restated Employment Agreement Dear Sarah: Avidity Biosciences, Inc. (the “Company”) and you entered into that certain Amended and Restated Employment Agreement, dated as of May 15, 2020 (the “Prior Agreement”). |
|
| November 7, 2024 |
Amended and Restated Employment Agreement, dated August 26, 2024, by and between rna-20240930xex104amende Exhibit 10.4 US-DOCS\152924018.1 August 26, 2024 VIA EMAIL W. Michael Flanagan, Ph.D. c/o Avidity Biosciences, Inc. 10578 Science Center Drive, Suite 125 San Diego, CA 92121 Re: Amended and Restated Employment Agreement Dear Mike: Avidity Biosciences, Inc. (the “Company”) and you entered into that certain Employment Agreement, dated as of December 8, 2020 (the “Prior Agree |
|
| November 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2024 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-39321 Avidity Biosciences, Inc. (Exact |
|
| November 7, 2024 |
Exhibit 99.1 Avidity Biosciences Reports Third Quarter 2024 Financial Results and Recent Highlights Enrollment in global Phase 3 HARBORTM study for del-desiran in DM1 is on track Avidity initiated biomarker cohort for del-brax FORTITUDETM study for FSHD; pursuing a potential accelerated approval path for del-brax Reported positive del-zota data from Phase 1/2 EXPLORE44TM trial for DMD44 Avidity to |
|
| October 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 30, 2024 AVIDITY BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39321 46-1336960 (State or other jurisdiction of incorporation or organi |
|
| October 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 3, 2024 AVIDITY BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39321 46-1336960 (State or other jurisdiction of incorporation or organiz |
|
| August 23, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 4) Avidity Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 05370A108 (CUSIP Number |
|
| August 15, 2024 |
Exhibit 1.1 7,320,000 Shares AVIDITY BIOSCIENCES, INC. Common Stock UNDERWRITING AGREEMENT August 14, 2024 LEERINK PARTNERS LLC TD SECURITIES (USA) LLC As Representatives of the several Underwriters c/o Leerink Partners LLC 53 State Street, 40th Floor Boston, MA 02109 c/o TD Securities (USA) LLC 1 Vanderbilt Avenue New York, New York 10017 Dear Sirs and Madams: 1. INTRODUCTORY. Avidity Biosciences |
|
| August 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 14, 2024 AVIDITY BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39321 46-1336960 (State or other jurisdiction of incorporation or organiz |
|
| August 15, 2024 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-279264 PROSPECTUS SUPPLEMENT (To Prospectus dated May 9, 2024) 7,320,000 Shares Common Stock We are offering 7,320,000 shares of our common stock. Our common stock is listed on the Nasdaq Global Market under the symbol “RNA.” On August 14, 2024, the last reported sales price of our common stock on the Nasdaq Global Market was $42.85 per share o |
|
| August 15, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form 424(b)(5) (Form Type) Avidity Biosciences, Inc. |
|
| August 15, 2024 |
Avidity Biosciences Announces Pricing of Upsized Public Offering of Common Stock SAN DIEGO, August 14, 2024 /PRNewswire/ – Avidity Biosciences, Inc. |
|
| August 15, 2024 |
Avidity Biosciences Announces Proposed Public Offering of Common Stock SAN DIEGO, August 13, 2024 /PRNewswire/ – Avidity Biosciences, Inc. |
|
| August 13, 2024 |
PRELIMINARY PROSPECTUS SUPPLEMENT (Subject to Completion) Dated August 13, 2024 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-279264 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been declared effective by the Securities and Exchange Commission. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these |
|
| August 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2024 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-39321 Avidity Biosciences, Inc. (Exact name |
|
| August 9, 2024 |
1 August 9, 2024 NASDAQ: RNA | aviditybio.com Investor & Analyst Event Series – Volume 10 Transforming Duchenne Muscular Dystrophy (DMD) AOC 1044 EXPLORE44TM Phase 1/2 Initial Data 2 We caution the reader that this presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements other than statements of historical fact contained in this presentation |
|
| August 9, 2024 |
As filed with the Securities and Exchange Commission on August 9, 2024 S-8 1 d895147ds8.htm S-8 As filed with the Securities and Exchange Commission on August 9, 2024 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 AVIDITY BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 46-1336960 (State or Other Jurisdiction of Incorporatio |
|
| August 9, 2024 |
Exhibit 107 CALCULATION OF FILING FEE TABLE Form S-8 (Form Type) Avidity Biosciences, Inc. |
|
| August 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 9, 2024 AVIDITY BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39321 46-1336960 (State or other jurisdiction of incorporation or organiza |
|
| August 9, 2024 |
Exhibit 99.1 Avidity Biosciences Reports Second Quarter 2024 Financial Results and Recent Highlights Avidity reports positive del-zota (AOC 1044) data; demonstrated 25% increase in dystrophin production and reduction of creatine kinase levels to near normal in people living with DMD44 in Phase 1/2 EXPLORE44™ trial Initiated global Phase 3 HARBOR™ trial and began administration of del-desiran in pe |
|
| August 9, 2024 |
Exhibit 10.2 AVIDITY BIOSCIENCES, INC. $400,000,000 COMMON STOCK SALES AGREEMENT August 9, 2024 TD Securities (USA) LLC 1 Vanderbilt Avenue New York, New York 10017 Ladies and Gentlemen: Avidity Biosciences, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with TD Securities (USA) LLC (“TD Cowen”), as follows: 1. Issuance and Sale of Placement Shares. The Com |
|
| August 9, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) Avidity Biosciences, Inc. |
|
| August 9, 2024 |
424B5 1 d851103d424b5.htm 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-279264 PROSPECTUS SUPPLEMENT (To Prospectus dated May 9, 2024) $400,000,000 Common Stock We have entered into a sales agreement, or the Sales Agreement, with TD Securities (USA) LLC, or TD Cowen, relating to shares of our common stock, par value $0.0001 per share, offered by this prospectus supp |
|
| August 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 9, 2024 AVIDITY BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39321 46-1336960 (State or other jurisdiction of incorporation or organiza |
|
| June 14, 2024 |
Exhibit 99.2 Avidity Biosciences, Inc. Announces Pricing of Public Offering of Common Stock SAN DIEGO, June 13, 2024 /PRNewswire/ – Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced the pricing of an underwritten public offering of 10,550,000 shares of its |
|
| June 14, 2024 |
Exhibit 1.1 10,550,000 Shares AVIDITY BIOSCIENCES, INC. Common Stock UNDERWRITING AGREEMENT June 13, 2024 TD SECURITIES (USA) LLC LEERINK PARTNERS LLC As Representatives of the several Underwriters c/o TD Securities (USA) LLC 1 Vanderbilt Avenue New York, New York 10017 c/o Leerink Partners LLC 53 State Street, 40th Floor Boston, MA 02109 Dear Sirs and Madams: 1. INTRODUCTORY. Avidity Biosciences, |
|
| June 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 13, 2024 AVIDITY BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39321 46-1336960 (State or other jurisdiction of incorporation or organizat |
|
| June 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 13, 2024 AVIDITY BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39321 46-1336960 (State or other jurisdiction of incorporation or organizat |
|
| June 14, 2024 |
Exhibit 99.1 Avidity Biosciences, Inc. Announces Proposed Public Offering of Common Stock SAN DIEGO, June 12, 2024 /PRNewswire/ – Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that it intends to offer and sell, subject to market and other conditions, $3 |
|
| June 14, 2024 |
10,550,000 Shares Common Stock Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-279264 PROSPECTUS SUPPLEMENT (To Prospectus dated May 9, 2024) 10,550,000 Shares Common Stock We are offering 10,550,000 Shares of our common stock. Our common stock is listed on the Nasdaq Global Market under the symbol “RNA.” On June 13, 2024, the last reported sales price of our common stock on the Nasdaq Global Market was |
|
| June 14, 2024 |
Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) Avidity Biosciences, Inc. |
|
| June 12, 2024 |
Amendment to Avidity Biosciences, Inc. 2022 Employment Inducement Incentive Exhibit 10.1 AMENDMENT TO THE AVIDITY BIOSCIENCES, INC. 2022 EMPLOYMENT INDUCEMENT INCENTIVE AWARD PLAN THIS AMENDMENT TO THE AVIDITY BIOSCIENCES, INC. 2022 EMPLOYMENT INDUCEMENT INCENTIVE AWARD PLAN (this “Amendment”), effective as of June 10, 2024, is made and adopted by Avidity Biosciences, Inc., a Delaware corporation (the “Company”). Capitalized terms used but not otherwise defined herein sha |
|
| June 12, 2024 |
Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-279264 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been declared effective by the Securities and Exchange Commission. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these |
|
| June 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 10, 2024 AVIDITY BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39321 46-1336960 (State or other jurisdiction of incorporation or organizat |
|
| June 12, 2024 |
1 June 12, 2024 NASDAQ: RNA | aviditybio.com Investor & Analyst Event Series – Volume 9 Transforming Facioscapulohumeral Muscular Dystrophy (FSHD) AOC 1020 FORTITUDETM Phase 1/2 Initial Data 2 Forward-Looking Statements We caution the reader that this presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements other than statements of historica |
|
| May 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 14, 2024 AVIDITY BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39321 46-1336960 (State or other jurisdiction of incorporation or organizati |
|
| May 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| May 9, 2024 |
mended and Restated Non-Employee Director Com Exhibit 10.1 AVIDITY BIOSCIENCES, INC. NON-EMPLOYEE DIRECTOR COMPENSATION PROGRAM (As Amended and Restated Effective April 19, 2024) Non-employee members of the board of directors (the “Board”) of Avidity Biosciences, Inc. (the “Company”) shall receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (as amended to date, this “Program”). This Program has |
|
| May 9, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) Avidity Biosciences, Inc. |
|
| May 9, 2024 |
Exhibit 99.1 Avidity Biosciences Reports First Quarter 2024 Financial Results and Recent Highlights Initiation of global Phase 3 HARBOR™ trial for del-desiran (AOC 1001) in DM1 on track for this quarter Avidity to report FSHD data from FORTITUDE™ trial this quarter and DMD data from EXPLORE44™ trial in 2H24 Presented positive long-term del-desiran data from MARINA-OLE™ showing reversal of disease |
|
| May 9, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2024 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-39321 Avidity Biosciences, Inc. (Exact name |
|
| May 9, 2024 |
As filed with the Securities and Exchange Commission on May 9, 2024 As filed with the Securities and Exchange Commission on May 9, 2024 Registration No. |
|
| May 9, 2024 |
Exhibit 4.4 AVIDITY BIOSCIENCES, INC. INDENTURE Dated as of , 20 [ ] Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions. 1 Section 1.2. Other Definitions. 5 Section 1.3. Incorporation by Reference of Trust Indenture Act. 5 Section 1.4. Rules of Construction. 6 ARTICLE II. THE SECURITIES 6 Section 2.1. Issuable in Series. 6 Section 2.2. E |
|
| May 9, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 9, 2024 AVIDITY BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39321 46-1336960 (State or other jurisdiction of incorporation or organizatio |
|
| May 6, 2024 |
RNA / Avidity Biosciences, Inc. / RA CAPITAL MANAGEMENT, L.P. - SC 13G Passive Investment SC 13G 1 tm2413656d1sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Avidity Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 05370A108 (CUSIP Number) April 26, 2024 (Date of Event Which Requires Filing of this Statement) Check |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin |
|
| April 26, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| April 2, 2024 |
As filed with the Securities and Exchange Commission on April 2, 2024 As filed with the Securities and Exchange Commission on April 2, 2024 Registration No. |
|
| April 2, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) Avidity Biosciences, Inc. |
|
| March 4, 2024 |
Investor & Analyst Event Series – Volume 8 TRANSFORMING MYOTONIC DYSTROPHY Global Phase 3 HARBOR Trial & Long-term MARINA-OLE Data March 4, 2024 NASDAQ: RNA | aviditybio. |
|
| March 4, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 4, 2024 AVIDITY BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39321 46-1336960 (State or other jurisdiction of incorporation or organizat |
|
| March 1, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 3) Avidity Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 05370A108 (CUSIP Number |
|
| February 29, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Avidity Biosciences, Inc. |
|
| February 29, 2024 |
Exhibit 4.1 THE SECURITIES EVIDENCED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY OTHER APPLICABLE SECURITIES LAWS AND HAVE BEEN ISSUED IN RELIANCE UPON AN EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND SUCH OTHER SECURITIES LAWS. NEITHER THIS SECURITY NOR ANY INTEREST OR PARTICIPATION HEREIN MAY BE |
|
| February 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 28, 2024 AVIDITY BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39321 46-1336960 (State or other jurisdiction of incorporation or organ |
|
| February 29, 2024 |
Exhibit 99.1 Avidity Biosciences Announces Oversubscribed $400 Million Private Placement Funding from new and existing investors, including Adage Capital Partners LP, Boxer Capital, Casdin Capital, LLC, Farallon, Janus Henderson Investors, RA Capital Management, RTW Investments, Wellington Management, as well as multiple large investment management firms Pro forma cash, cash equivalents and invest |
|
| February 29, 2024 |
ary 28, 2024, by and between Avidity Biosciences, Inc. and each of the purchasers party thereto Exhibit 10.1 AVIDITY BIOSCIENCES, INC. SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (the “Agreement”) is made as of February 28, 2024 (the “Effective Date”), by and between Avidity Biosciences, Inc., a Delaware corporation (the “Company”), and each of the purchasers whose names are set forth on Schedule A hereto (each, a “Purchaser” and, collectively, the “Purchasers”). Whereas |
|
| February 29, 2024 |
As filed with the Securities and Exchange Commission on February 29, 2024 As filed with the Securities and Exchange Commission on February 29, 2024 Registration No. |
|
| February 28, 2024 |
Avidity Biosciences, Inc. Policy for Recovery of Erroneously Awarded Compensation. Exhibit 97.1 AVIDITY BIOSCIENCES POLICY FOR RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION Avidity Biosciences, Inc. (the “Company”) has adopted this Policy for Recovery of Erroneously Awarded Compensation (this “Policy”), effective as of October 2, 2023 (the “Effective Date”). Capitalized terms used in this Policy but not otherwise defined herein are defined in Section 11. 1.Persons Subject to Poli |
|
| February 28, 2024 |
Exhibit 10.2 AVIDITY BIOSCIENCES, INC. 2020 INCENTIVE AWARD PLAN ARTICLE I. PURPOSE The Plan’s purpose is to enhance the Company’s ability to attract, retain and motivate persons who make (or are expected to make) important contributions to the Company by providing these individuals with equity ownership opportunities. Capitalized terms used in the Plan are defined in Article XI. ARTICLE II. ELIGI |
|
| February 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 28, 2024 AVIDITY BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39321 46-1336960 (State or other jurisdiction of incorporation or organ |
|
| February 28, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) Avidity Biosciences, Inc. |
|
| February 28, 2024 |
ecurities Purchase Agreement, dated November 27, 2023, by and between Bristol Exhibit 10.14 Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Such omitted information has been noted in this document with a placeholder identified by the mark “[***]”. SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of November |
|
| February 28, 2024 |
As filed with the Securities and Exchange Commission on February 28, 2024 As filed with the Securities and Exchange Commission on February 28, 2024 Registration No. |
|
| February 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number: 001-39321 AVIDITY BIOSCIENCES, INC. |
|
| February 28, 2024 |
Exhibit 99.1 Avidity Biosciences Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Highlights Avidity is on-track to initiate global Phase 3 HARBOR™ trial of AOC 1001 for DM1 in mid-2024 Company to share first-look at long-term efficacy and safety data from MARINA-OLE™ trial in people living with DM1 at MDA Clinical & Scientific Conference and via webcast on March 4, 2024 Avidi |
|
| February 28, 2024 |
Subsidiaries of the Registrant. Exhibit 21.1 Subsidiaries Entity Name State or Other Jurisdiction of Organization Avidity Biosciences Ireland Limited Republic of Ireland |
|
| February 28, 2024 |
esearch Collaboration and License Agreement, dated November 27, 2023, by and between Bristol Exhibit 10.13 Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Such omitted information has been noted in this document with a placeholder identified by the mark “[***]”. RESEARCH COLLABORATION AND LICENSE AGREEMENT between AVIDITY BIOSCIENCES, INC. and BRISTOL MYERS SQUIBB COMP |
|
| February 14, 2024 |
Exhibit 1: Joint filing agreement EX-99.1 2 tm246065d5ex1.htm EXHIBIT 1 EXHIBIT 1 AGREEMENT This Joint Filing Agreement, dated as of February 14, 2024, is by and among RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (the foregoing are collectively referred to herein as the “Filers”). Each of the Filers may be required to file with the United States Securities and Exchange Commission |
|
| February 14, 2024 |
RNA / Avidity Biosciences, Inc. / RA CAPITAL MANAGEMENT, L.P. - SC 13G/A Passive Investment SC 13G/A 1 tm246065d5sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* AVIDITY BIOSCIENCES, INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 05370A108 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Stateme |
|
| February 13, 2024 |
RNA / Avidity Biosciences, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Avidity Biosciences Inc Title of Class of Securities: Common Stock CUSIP Number: 05370A108 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule pursuant to which this Schedule is file |
|
| February 9, 2024 |
RNA / Avidity Biosciences, Inc. / FMR LLC Passive Investment SCHEDULE 13G Amendment No.6 AVIDITY BIOSCIENCES INC COMMON STOCK Cusip #05370A108 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #05370A108 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 10,400,902 Item 6: 0 Item 7: 10,404,096 Item 8: 0 Item 9: 10,404,096 Item |
|
| February 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Avidity Biosciences, Inc (Name of Issuer) Common Stock (Title of Class of Securities) 05370A108 (CUSIP Number) December 29, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which thi |
|
| January 24, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 2) Avidity Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 05370A108 (CUSIP Number |
|
| January 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 31, 2023 AVIDITY BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39321 46-1336960 (State or other jurisdiction of incorporation or organ |
|
| December 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 13, 2023 AVIDITY BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39321 46-1336960 (State or other jurisdiction of incorporation or organ |
|
| December 13, 2023 |
Amended and Restated Bylaws (marked cpredline-avidityxboard AMENDED AND RESTATED BYLAWS OF AVIDITY BIOSCIENCES, INC. (a Delaware corporation) As Amended and Restated December 12, 2023 Exhibit 3.2 -i- TABLE OF CONTENTS Page ARTICLE I - CORPORATE OFFICES ............................................................................................... 1 1.1 REGISTERED OFFICE ............................................................... |
|
| December 13, 2023 |
avidity-arbylawsasofdece Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF AVIDITY BIOSCIENCES, INC. (a Delaware corporation) As Amended and Restated December 12, 2023 -i- TABLE OF CONTENTS Page ARTICLE I - CORPORATE OFFICES ............................................................................................... 1 1.1 REGISTERED OFFICE .............................................................. |
|
| December 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 12, 2023 AVIDITY BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39321 46-1336960 (State or other jurisdiction of incorporation or organ |
|
| December 4, 2023 |
RNA / Avidity Biosciences Inc / BRISTOL MYERS SQUIBB CO - SC 13G Passive Investment SC 13G 1 ef20016011sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.)* Avidity Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 05370A108 (CUSIP Number) November 27, 2023 (Date of Event Which Requires Filing of This Statement) Check |
|
| November 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 27, 2023 AVIDITY BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39321 46-1336960 (State or other jurisdiction of incorporation or organ |
|
| November 8, 2023 |
Exhibit 99.1 Avidity Biosciences Reports Third Quarter 2023 Financial Results and Recent Highlights Avidity reported new positive AOC 1001 data at World Muscle Society (WMS) Congress in October demonstrating consistent improvement in multiple additional functional endpoints and favorable long-term safety and tolerability in people living with myotonic dystrophy type 1 (DM1) AOC 1044 receives Orpha |
|
| November 8, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 8, 2023 AVIDITY BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39321 46-1336960 (State or other jurisdiction of incorporation or organi |
|
| November 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2023 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-39321 Avidity Biosciences, Inc. (Exact |
|
| October 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 7, 2023 AVIDITY BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39321 46-1336960 (State or other jurisdiction of incorporation or organiz |
|
| August 8, 2023 |
Exhibit 99.1 Avidity Biosciences Reports Second Quarter 2023 Financial Results and Recent Highlights Advancing three clinical development programs – DM1, DMD, FSHD - with data anticipated from each program over the next 12 months SAN DIEGO, Aug. 8, 2023 /PRNewswire/- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called |
|
| August 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2023 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-39321 Avidity Biosciences, Inc. (Exact name |
|
| August 8, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 8, 2023 AVIDITY BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39321 46-1336960 (State or other jurisdiction of incorporation or organiza |
|
| July 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 10, 2023 AVIDITY BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39321 46-1336960 (State or other jurisdiction of incorporation or organizat |
|
| June 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 15, 2023 AVIDITY BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39321 46-1336960 (State or other jurisdiction of incorporation or organizat |
|
| May 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 17, 2023 AVIDITY BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39321 46-1336960 (State or other jurisdiction of incorporation or organizati |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 9, 2023 AVIDITY BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39321 46-1336960 (State or other jurisdiction of incorporation or organizatio |
|
| May 9, 2023 |
Amended and Restated Non-Employee Director Compensation Program Exhibit 10.1 AVIDITY BIOSCIENCES, INC. NON-EMPLOYEE DIRECTOR COMPENSATION PROGRAM (As Amended and Restated Effective April 25, 2023) Non-employee members of the board of directors (the “Board”) of Avidity Biosciences, Inc. (the “Company”) shall receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (as amended to date, this “Program”). This Program has |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2023 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-39321 Avidity Biosciences, Inc. (Exact name |
|
| May 9, 2023 |
Exhibit 99.1 Avidity Biosciences Reports First Quarter 2023 Financial Results and Recent Highlights Positive Topline Data from AOC 1001 Phase 1/2 MARINA™ Trial Demonstrated Functional Improvement, Disease Modification and Favorable Safety and Tolerability Profile in People Living with Myotonic Dystrophy Type 1 Advancing three programs in clinical trials with data expected later this year - first l |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin |
|
| April 28, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| April 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 27, 2023 AVIDITY BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39321 46-1336960 (State or other jurisdiction of incorporation or organiza |
|
| April 27, 2023 |
a04-27x23vol7marinatopli 1 Investor & Analyst Event Series – Volume 7 AOC 1001 MARINATM Phase 1/2 Topline Data Kristl, Zen & Loraine living with DM1 Nathan living with DMD Josh living with FSHD 2 Forward-Looking Statements We caution the reader that this presentation contains forward-looking statements that involve substantial risks and uncertainties. |
|
| March 30, 2023 |
Regulation FD Disclosure, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 30, 2023 AVIDITY BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39321 46-1336960 (State or other jurisdiction of incorporation or organiza |
|
| February 28, 2023 |
Avidity Biosciences Reports Fourth Quarter and Year-End 2022 Financial Results and Recent Highlights Exhibit 99.1 Avidity Biosciences Reports Fourth Quarter and Year-End 2022 Financial Results and Recent Highlights SAN DIEGO, February 28, 2023 / PRNewswire/ - Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today reported financial results for the fourth quarter and year |
|
| February 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 28, 2023 AVIDITY BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39321 46-1336960 (State or other jurisdiction of incorporation or organ |
|
| February 28, 2023 |
Exhibit 10.2 AVIDITY BIOSCIENCES, INC. 2020 INCENTIVE AWARD PLAN ARTICLE I. PURPOSE The Plan’s purpose is to enhance the Company’s ability to attract, retain and motivate persons who make (or are expected to make) important contributions to the Company by providing these individuals with equity ownership opportunities. Capitalized terms used in the Plan are defined in Article XI. ARTICLE II. ELIGI |
|
| February 28, 2023 |
Exhibit 10.5 AVIDITY BIOSCIENCES, INC. 2022 EMPLOYMENT INDUCEMENT INCENTIVE AWARD PLAN ARTICLE I. PURPOSE The Plan’s purpose is to enhance the Company’s ability to attract, retain and motivate Eligible Persons who are expected to make important contributions to the Company by providing these individuals with equity ownership opportunities. Capitalized terms used in the Plan are defined in Article |
|
| February 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2022 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number: 001-39321 AVIDITY BIOSCIENCES, INC. |
|
| February 28, 2023 |
Exhibit 10.7 February 23, 2023 Arthur A. Levin, Ph.D. c/o Avidity Biosciences, Inc. 10578 Science Center Drive, Suite 125 San Diego, CA 92121 Re: Second Amended and Restated Employment Agreement Dear Art: Avidity Biosciences, Inc. (the “Company”) and you entered into that certain Amended and Restated Employment Agreement, dated as of May 15, 2020 (the “Original Agreement”). The Company and you des |
|
| February 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 22, 2023 AVIDITY BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39321 46-1336960 (State or other jurisdiction of incorporation or organ |
|
| February 14, 2023 |
RNA / Prosensa Holding N.v. In Liquidatie / EcoR1 Capital, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2) Avidity Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 05370A108 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate t |
|
| February 9, 2023 |
RNA / Prosensa Holding N.v. In Liquidatie / VANGUARD GROUP INC - SCHEDULE 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: Avidity Biosciences Inc. Title of Class of Securities: Common Stock CUSIP Number: 05370A108 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d-1(b) |
|
| February 3, 2023 |
RNA / Prosensa Holding N.v. In Liquidatie / STATE STREET CORP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 INITIAL FILING AVIDITY BIOSCIENCES INC (NAME OF ISSUER) COMMON STOCK (TITLE OF CLASS OF SECURITIES) 05370A108 (CUSIP NUMBER) 12/31/2022 (DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT) CHECK THE APPROPRIATE BOX TO DESIGNATE THE RULE PURSUANT TO WHICH THIS SCHEDULE I |
|
| February 2, 2023 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 1) Avidity Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 05370A108 (CUSIP Number |
|
| January 11, 2023 |
SC 13G/A 1 rnaa111123.htm COWEN FINANCIAL PRODUCTS LLC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Avidity Biosciences, Inc (Name of Issuer) Common Stock (Title of Class of Securities) 05370A108 (CUSIP Number) December 30, 2022 (Date of Event which Requires Filing of this Statement) Check the appr |
|
| December 30, 2022 |
RNA / Prosensa Holding N.v. In Liquidatie / RA CAPITAL MANAGEMENT, L.P. - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* AVIDITY BIOSCIENCES, INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 05370A108 (CUSIP Number) December 20, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate t |
|
| December 27, 2022 |
RNA / Prosensa Holding N.v. In Liquidatie / Cormorant Asset Management, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Avidity Biosciences, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 05370A108 (CUSIP Number) December 14, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which thi |
|
| December 27, 2022 |
Exhibit 99.1 JOINT FILING AGREEMENT This Joint Filing Agreement, dated as of December 27, 2022, is by and among Cormorant Global Healthcare Master Fund, LP, Cormorant Global Healthcare GP, LLC, Cormorant Private Healthcare Fund II, LP, Cormorant Private Healthcare GP II, LLC, Cormorant Asset Management, LP and Bihua Chen (collectively, the ?Filers?). Each of the Filers may be required to file with |
|
| December 21, 2022 |
As filed with the Securities and Exchange Commission on December 21, 2022 S-8 As filed with the Securities and Exchange Commission on December 21, 2022 Registration No. |
|
| December 21, 2022 |
EX-10.2 Exhibit 10.2 AVIDITY BIOSCIENCES, INC. 2022 EMPLOYMENT INDUCEMENT INCENTIVE AWARD PLAN ARTICLE I. PURPOSE The Plan’s purpose is to enhance the Company’s ability to attract, retain and motivate Eligible Persons who are expected to make important contributions to the Company by providing these individuals with equity ownership opportunities. Capitalized terms used in the Plan are defined in |
|
| December 21, 2022 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Avidity Biosciences, Inc. |
|
| December 16, 2022 |
12,000,000 Shares Common Stock 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-257691 PROSPECTUS SUPPLEMENT (To Prospectus dated July 2, 2021) 12,000,000 Shares Common Stock We are offering 12,000,000 shares of our common stock. Our common stock is listed on the Nasdaq Global Market under the symbol “RNA.” On December 15, 2022, the last reported sales price of our common stock on the Nasdaq Global |
|
| December 16, 2022 |
Avidity Biosciences, Inc. Announces Pricing of Upsized Public Offering of Common Stock EX-99.2 Exhibit 99.2 Avidity Biosciences, Inc. Announces Pricing of Upsized Public Offering of Common Stock SAN DIEGO, December 15, 2022 /PRNewswire/ – Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced the pricing of an underwritten public offering of 12,00 |
|
| December 16, 2022 |
EX-1.1 2 d407691dex11.htm EX-1.1 Exhibit 1.1 12,000,000 Shares AVIDITY BIOSCIENCES, INC. Common Stock UNDERWRITING AGREEMENT December 15, 2022 COWEN AND COMPANY, LLC EVERCORE GROUP L.L.C. WELLS FARGO SECURITIES, LLC As Representatives of the several Underwriters c/o Cowen and Company, LLC 599 Lexington Avenue New York, New York 10022 c/o Evercore Group L.L.C. 55 East 52nd Street New York, New York |
|
| December 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 15, 2022 AVIDITY BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39321 46-1336960 (State or other jurisdiction of incorporation or organ |
|
| December 16, 2022 |
EX-FILING FEES 2 d432139dexfilingfees.htm EX107 Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) Avidity Biosciences, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate |
|
| December 16, 2022 |
Avidity Biosciences, Inc. Announces Proposed Public Offering of Common Stock EX-99.1 Exhibit 99.1 Avidity Biosciences, Inc. Announces Proposed Public Offering of Common Stock SAN DIEGO, December 15, 2022 /PRNewswire/ – Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that it intends to offer and sell, subject to market and other co |
|
| December 15, 2022 |
424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-257691 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been declared effective by the Securities and Exchange Commission. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell |
|
| December 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 14, 2022 AVIDITY BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39321 46-1336960 (State or other jurisdiction of incorporation or organ |
|
| December 14, 2022 |
EX-99.1 Virtual Investor & Analyst Event Series – Volume 6: AOC 1001 MARINATM Phase 1/2 Trial Preliminary Data Assessment Exhibit 99.1 Forward Looking Statements We caution the reader that this presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this presentation, including, but not |
|
| December 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 1, 2022 AVIDITY BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39321 46-1336960 (State or other jurisdiction of incorporation or organi |
|
| November 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-39321 Avidity Biosciences, Inc. (Exact name of registrant |
|
| November 8, 2022 |
Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) Avidity Biosciences, Inc. |
|
| November 8, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 8, 2022 AVIDITY BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39321 46-1336960 (State or other jurisdiction of incorporation or organi |
|
| November 8, 2022 |
Exhibit 99.1 Avidity Biosciences Reports Third Quarter 2022 Financial Results and Recent Highlights Company has three distinct rare disease programs in clinical development - myotonic dystrophy type 1 (DM1), facioscapulohumeral muscular dystrophy (FSHD), and Duchenne muscular dystrophy (DMD) On track for preliminary assessment of AOC 1001 MARINATM trial in fourth quarter SAN DIEGO, November 8, 202 |
|
| November 8, 2022 |
Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-257691 PROSPECTUS SUPPLEMENT (To Prospectus dated July 2, 2021) $200,000,000 Common Stock We have entered into a sales agreement, or the Sales Agreement, with Cowen and Company, LLC, or Cowen, relating to shares of our common stock, par value $0.0001 per share, offered by this prospectus supplement. In accordance with the term |
|
| November 8, 2022 |
Exhibit 10.1 Execution Version Avidity Biosciences, Inc. $200,000,000 COMMON STOCK SALES AGREEMENT November 8, 2022 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: Avidity Biosciences, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows: 1. Issuance and Sale of Placement Share |
|
| October 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 13, 2022 AVIDITY BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39321 46-1336960 (State or other jurisdiction of incorporation or organi |
|
| October 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 3, 2022 AVIDITY BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39321 46-1336960 (State or other jurisdiction of incorporation or organiz |
|
| September 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 27, 2022 AVIDITY BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39321 46-1336960 (State or other jurisdiction of incorporation or orga |
|
| August 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Avidity Biosciences, Inc (Name of Issuer) Common Stock (Title of Class of Securities) 05370A108 (CUSIP Number) August 05, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: |
|
| August 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-39321 Avidity Biosciences, Inc. (Exact name of registrant as s |
|
| August 9, 2022 |
Exhibit 99.1 Avidity Biosciences Reports Second Quarter 2022 Financial Results and Recent Highlights Company remains on track to have three programs in the clinic by the end of this year Programs are for three distinct rare diseases - myotonic dystrophy type 1 (DM1), facioscapulohumeral muscular dystrophy (FSHD) and Duchenne muscular dystrophy (DMD) SAN DIEGO, August 9, 2022 / PRNewswire/- Avidity |
|
| August 9, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 9, 2022 AVIDITY BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39321 46-1336960 (State or other jurisdiction of incorporation or organiza |
|
| August 9, 2022 |
Amended and Restated Non-Employee Director Compensation Policy. Exhibit 10.1 AVIDITY BIOSCIENCES, INC. NON-EMPLOYEE DIRECTOR COMPENSATION PROGRAM (As Amended and Restated Effective June 2, 2022) Non-employee members of the board of directors (the ?Board?) of Avidity Biosciences, Inc. (the ?Company?) shall receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (as amended to date, this ?Program?). This Program has b |
|
| June 17, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 15, 2022 AVIDITY BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39321 46-1336960 (State or other jurisdiction of incorporation or organizat |
|
| May 10, 2022 |
Avidity Biosciences Reports First Quarter 2022 Financial Results and Recent Highlights Exhibit 99.1 Avidity Biosciences Reports First Quarter 2022 Financial Results and Recent Highlights SAN DIEGO, May 10, 2022 / PRNewswire/- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs?), today announced financial results for the first quarter ended March 31, 2022 and hig |
|
| May 10, 2022 |
As filed with the Securities and Exchange Commission on May 10, 2022 As filed with the Securities and Exchange Commission on May 10, 2022 Registration No. |
|
| May 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-39321 Avidity Biosciences, Inc. (Exact name of registrant as |
|
| May 10, 2022 |
Employment Agreement, dated August 14, 2020, by and between Teresa McCarthy and the Registrant. Exhibit 10.1 August 14, 2020 Teresa McCarthy c/o Avidity Biosciences, Inc. 10975 N. Torrey Pines Rd., Suite 150 La Jolla, CA 92037 Re:Offer of Employment Dear Teresa: Avidity Biosciences, Inc. (the "Company") is pleased to offer you employment as the Company's Chief Human Resources Officer on the terms and conditions set forth in this letter agreement (the "Agreement"). 1.Commencement of Employmen |
|
| May 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 10, 2022 AVIDITY BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39321 46-1336960 (State or other jurisdiction of incorporation or organizati |
|
| May 10, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Avidity Biosciences, Inc. |
|
| April 29, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| April 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| March 1, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 1, 2022 AVIDITY BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39321 46-1336960 (State or other jurisdiction of incorporation or organizat |
|
| March 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number: 001-39321 AVIDITY BIOSCIENCES, INC. |
|
| March 1, 2022 |
Consulting Agreement, dated January 22, 2022, by and between Joseph Baroldi and the Registrant Exhibit 10.12 CONSULTING AGREEMENT (Non-HCP) This Consulting Agreement (the ?Agreement?) is entered into and effective 22 January 2022 (the ?Effective Date?) by and between Joseph Baroldi (?Consultant?) and Avidity Biosciences, Inc. (?Avidity?), a Delaware corporation, with offices located at 10578 Science Center Drive, Suite 125, San Diego, California 92121, USA. Consultant and Avidity shall be r |
|
| March 1, 2022 |
Avidity Biosciences Reports Fourth Quarter and Year-End 2021 Financial Results and Recent Highlights Exhibit 99.1 Avidity Biosciences Reports Fourth Quarter and Year-End 2021 Financial Results and Recent Highlights SAN DIEGO, March 1, 2022 /PRNewswire/- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs?), today reported financial results for the fourth quarter and year ended |
|
| February 14, 2022 |
RNA / Prosensa Holding N.v. In Liquidatie / FEDERATED HERMES, INC. Passive Investment OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ?.11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. *) AVIDITY BIOSCIENCES LLC (Name of Issuer) COMMON STOCK (Title of Class of Securities) 05370A108 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of thi |
|
| February 14, 2022 |
RNA / Prosensa Holding N.v. In Liquidatie / EcoR1 Capital, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) Avidity Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 05370A108 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate t |
|
| February 14, 2022 |
RNA / Prosensa Holding N.v. In Liquidatie / Cormorant Asset Management, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Avidity Biosciences, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 05370A108 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which th |
|
| February 10, 2022 |
Exhibit 99.1 Power of Attorney The undersigned, ELI LILLY AND COMPANY, a corporation duly organized under the laws of the State of Indiana, United States (the ?Company?), does hereby make, constitute and appoint each of Anat Hakim, Christopher Anderson and Jonathan Groff acting severally, as its true and lawful attorneys-in-fact, for the purpose of, from time to time, executing in its name and on |
|
| February 10, 2022 |
RNA / Prosensa Holding N.v. In Liquidatie / ELI LILLY & Co - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No: 1)* Avidity Biosciences, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 05370A108 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| January 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 4, 2022 AVIDITY BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39321 46-1336960 (State or other jurisdiction of incorporation or organiz |
|
| December 9, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 9, 2021 AVIDITY BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39321 46-1336960 (State or other jurisdiction of incorporation or organi |
|
| December 9, 2021 |
Virtual Investor & Analyst Event Series ? Volume 3 Delivering on AOCs: FSHD Exhibit 99. |
|
| November 9, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 9, 2021 AVIDITY BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39321 46-1336960 (State or other jurisdiction of incorporation or organi |
|
| November 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-39321 Avidity Biosciences, Inc. (Exact name of registrant |
|
| November 9, 2021 |
Exhibit 99.1 Avidity Biosciences Reports Third Quarter 2021 Financial Results and Recent Highlights Initiated the Phase 1/2 MARINATM trial of AOC 1001, marking the first AOC in clinical development On track to have three clinical programs by the end of 2022 Volume 3, Virtual Investor and Analyst Series, on December 9 at 11am ET featuring Jeffrey Statland, M.D., an expert and leading physician trea |
|
| November 9, 2021 |
Exhibit 10.2 GENERAL RELEASE OF CLAIMS THIS GENERAL RELEASE OF CLAIMS (this ?Release?) is entered into by and between Avidity Biosciences, Inc., a Delaware corporation (the ?Company?), and Jae B. Kim, M.D. (?Executive?), as of the Effective Date (as defined below). WHEREAS, the Company and Executive are parties to that certain employment letter agreement dated as of July 6, 2020 (the ?Employment A |
|
| September 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 26, 2021 AVIDITY BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39321 46-1336960 (State or other jurisdiction of incorporation or organiz |
|
| August 25, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 24, 2021 AVIDITY BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39321 46-1336960 (State or other jurisdiction of incorporation or organiz |
|
| August 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-39321 Avidity Biosciences, Inc. (Exact name of registrant as s |
|
| August 9, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 9, 2021 AVIDITY BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39321 46-1336960 (State or other jurisdiction of incorporation or organiza |
|
| August 9, 2021 |
Avidity Biosciences Reports Second Quarter 2021 Financial Results and Recent Highlights Exhibit 99.1 Avidity Biosciences Reports Second Quarter 2021 Financial Results and Recent Highlights LA JOLLA, Calif., Aug. 9, 2021 /PRNewswire/- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs?), today reported financial results for the second quarter and six months ended |
|
| August 4, 2021 |
Avidity Biosciences, Inc. Announces Proposed Public Offering of Common Stock Exhibit 99.1 Avidity Biosciences, Inc. Announces Proposed Public Offering of Common Stock LA JOLLA, Calif., August 2, 2021 /PRNewswire/ ? Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs?), today announced that it intends to offer and sell, subject to market and other condit |
|
| August 4, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 3, 2021 AVIDITY BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39321 46-1336960 (State or other jurisdiction of incorporation or organiza |
|
| August 4, 2021 |
Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-257691 CALCULATION OF REGISTRATION FEE TITLE OF EACH CLASS OF SECURITIES TO BE REGISTERED AMOUNT TO BE REGISTERED PROPOSED MAXIMUM OFFERING PRICE PER SHARE PROPOSED MAXIMUM AGGREGATE OFFERING PRICE AMOUNT OF REGISTRATION FEE(2) Common Stock, $0.0001 par value per share 9,200,000(1) $18.00 $165,600,000 $18,067 (1) Includes shar |
|
| August 4, 2021 |
Exhibit 1.1 8,000,000 Shares AVIDITY BIOSCIENCES, INC. Common Stock UNDERWRITING AGREEMENT August 3, 2021 COWEN AND COMPANY, LLC SVB LEERINK LLC EVERCORE GROUP L.L.C. WELLS FARGO SECURITIES, LLC As Representatives of the several Underwriters c/o Cowen and Company, LLC 599 Lexington Avenue New York, New York 10022 c/o SVB Leerink LLC 53 State Street, 40th Floor Boston, Massachusetts 02109 c/o Everc |
|
| August 4, 2021 |
Avidity Biosciences, Inc. Announces Pricing of Public Offering of Common Stock Exhibit 99.2 Avidity Biosciences, Inc. Announces Pricing of Public Offering of Common Stock LA JOLLA, Calif., August 3, 2021 /PRNewswire/ ? Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs?), today announced the pricing of an underwritten public offering of 8,000,000 shares |
|
| August 2, 2021 |
Virtual Investor & Analyst Event Series ? Volume 2 : AOC 1001 Exhibit 99.1 Forward Looking Statements We caution the reader that this presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial |
|
| August 2, 2021 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 2, 2021 AVIDITY BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39321 46-1336960 (State or other jurisdiction of incorporation or organiza |
|
| August 2, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 2, 2021 AVIDITY BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39321 46-1336960 (State or other jurisdiction of incorporation or organiza |
|
| August 2, 2021 |
Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-257691 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been declared effective by the Securities and Exchange Commission. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these |
|
| July 2, 2021 |
Exhibit 4.4 AVIDITY BIOSCIENCES, INC. INDENTURE Dated as of , 20 [ ] Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions 1 Section 1.2. Other Definitions 4 Section 1.3. Incorporation by Reference of Trust Indenture Act 4 Section 1.4. Rules of Construction 5 ARTICLE II. THE SECURITIES 5 Section 2.1. Issuable in Series 5 Section 2.2. Establ |
|
| July 2, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 2, 2021 AVIDITY BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39321 46-1336960 (State or other jurisdiction of incorporation or organizati |
|
| July 2, 2021 |
As filed with the Securities and Exchange Commission on July 2, 2021 Table of Contents As filed with the Securities and Exchange Commission on July 2, 2021 Registration No. |
|
| July 2, 2021 |
Sales Agreement, dated July 2, 2021, between Avidity Biosciences, Inc. and Cowen and Company, LLC Exhibit 1.1 Execution Version AVIDITY BIOSCIENCES, INC. $150,000,000 OF SHARES OF COMMON STOCK PAR VALUE $0.0001 PER SHARE SALES AGREEMENT July 2, 2021 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: Avidity Biosciences, Inc., a Delaware corporation (the ?Company?), confirms its agreement (this ?Agreement?) with Cowen and Company, LLC (?Cowen?), as follows: 1. |
|
| July 2, 2021 |
Sales Agreement, dated July 2, 2021, by and between the Company and Cowen and Company, LLC Exhibit 1.2 Execution Version AVIDITY BIOSCIENCES, INC. $150,000,000 OF SHARES OF COMMON STOCK PAR VALUE $0.0001 PER SHARE SALES AGREEMENT July 2, 2021 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: Avidity Biosciences, Inc., a Delaware corporation (the ?Company?), confirms its agreement (this ?Agreement?) with Cowen and Company, LLC (?Cowen?), as follows: 1. |
|
| June 17, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 16, 2021 AVIDITY BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39321 46-1336960 (State or other jurisdiction of incorporation or organizat |
|
| May 19, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 19, 2021 AVIDITY BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39321 46-1336960 (State or other jurisdiction of incorporation or organizati |
|
| May 19, 2021 |
Virtual Investor & Analyst Event Series ? Volume 1 Engineering AOC?s Exhibit 99.1 Forward Looking Statements We caution the reader that this presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and fin |
|
| May 12, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 12, 2021 AVIDITY BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39321 46-1336960 (State or other jurisdiction of incorporation or organizati |
|
| May 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-39321 Avidity Biosciences, Inc. (Exact name of registrant as |
|
| May 12, 2021 |
Avidity Biosciences Reports First Quarter 2021 Financial Results and Recent Highlights EX-99.1 2 rna-ex9916.htm EX-99.1 Exhibit 99.1 Avidity Biosciences Reports First Quarter 2021 Financial Results and Recent Highlights LA JOLLA, Calif., May 12, 2021 /PRNewswire/- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs™), today reported financial results for the fi |
|
| April 29, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| April 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| March 15, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 15, 2021 AVIDITY BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39321 46-1336960 (State or other jurisdiction of incorporation or organiza |
|
| March 15, 2021 |
Non-Employee Director Compensation Program. Exhibit 10.4 AVIDITY BIOSCIENCES, INC. Non-Employee DIRECTOR COMPENSATION PROGRAM (As Amended and Restated Effective January 11, 2021) Non-employee members of the board of directors (the ?Board?) of Avidity Biosciences, Inc. (the ?Company?) shall receive cash and equity compensation as set forth in this Amended and Restated Non-Employee Director Compensation Program (this ?Program?). This Program |
|
| March 15, 2021 |
Exhibit 4.3 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of December 31, 2020, Avidity Biosciences, Inc. (?we,? ?us? and ?our?) had one class of securities registered pursuant to Section 12 of the Securities Exchange Act of 1934, as amended (the ?Exchange Act?): our common stock. Description of Common Stock General The follo |
|
| March 15, 2021 |
Exhibit 10.14 AMENDED AND RESTATED LEASE AGREEMENT THIS AMENDED AND RESTATED LEASE AGREEMENT AMENDS, RESTATES AND SUPERSEDES IN ITS ENTIRETY THAT CERTAIN LEASE AGREEMENT DATED AS OF June 1, 2020 (THE ?ORIGINAL LEASE?), BY AND BETWEEN TENANT (AS DEFINED BELOW) AND LANDLORD (AS DEFINED BELOW). THIS AMENDED AND RESTATED LEASE AGREEMENT (this ?Lease?) is made this 18 day of December, 2020, between ARE |
|
| March 15, 2021 |
Avidity Biosciences Reports Fourth Quarter and Year-End 2020 Financial Results and Recent Highlights Exhibit 99.1 Avidity Biosciences Reports Fourth Quarter and Year-End 2020 Financial Results and Recent Highlights LA JOLLA, Calif., March 15, 2021 /PRNewswire/- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs?), today reported financial results for the fourth quarter and |
|
| March 15, 2021 |
Exhibit 10.10 December 8, 2020 Mike Flanagan Re:Offer of Employment Dear Mike, Avidity Biosciences, Inc. (the ?Company?) is pleased to offer you employment as the Company?s Chief Technical Officer on the terms and conditions set forth in this letter agreement (the ?Agreement?). 1.Commencement of Employment. Your employment with the Company will start on or about January 21, 2021 (the ?Start Date?) |
|
| March 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number: 001-39321 AVIDITY BIOSCIENCES, INC. |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) Avidity Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 05370A108 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate th |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Avidity Biosciences, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 05370A108 (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which th |
|
| February 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Avidity Biosciences, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 05370A108 (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which th |
|
| January 21, 2021 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 21, 2021 AVIDITY BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39321 46-1336960 (State or other jurisdiction of incorporation |
